

We look forward to seeing you at the JCR booth (#9) and Seminar 4

WELCOME AND INTRODUCTION



Roberto Giugliani, MD, PhD Federal University of Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil



Takashi Hamazaki, MD, PhD
Osaka Metropolitan University Graduate School of Medicine
Osaka, Japan

OVERVIEW OF MUCOPOLYSACCHARIDOSIS (MPS) DISEASE STATE



Nicole Muschol, MD
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

LIVING WITH PATIENTS AND OBSERVING SUBTLE CHANGES IN OoL MEASURES.



Terri Klein, CNPM, MPA
National MPS Society
Durham, North Carolina, United States

PATIENT-REPORTED OUTCOMES IN MPS



Ana Maria Martins, MD, MSc, PhD Federal University of São Paulo São Paulo, Brazil

PANEL DISCUSSION

All (with questions submitted from the audience)

Mucopolysaccharidoses (MPS) are a group of inherited metabolic rare diseases caused by the deficiency of enzymes required to break down glycosaminoglycans (GAGs) in the lysosome. GAG accumulation can lead to damage to multiple organs and, in severe cases, progressive cognitive decline. In this symposium, we will review the current state of MPS and explore in depth how changes in quality-of-life measures and other patient-reported outcomes can influence research and patient care.





15th International Congress of Inborn Errors of Metabolism (ICIEM2025)

Luncheon Seminar 12



Blood-brain barrier penetrating AAV vector for the treatment of CNS diseases



September 5, 2025 12:00-13:00



Room 3 (Room B-1)

Kyoto International Conference Center (422 Iwakura Osagicho, Sakyo-ku, Kyoto, 606-0001, Japan)



Maurizio Scarpa, MD, PhD

Director, Regional Coordinating Center for Rare Diseases Udine University Hospital, Udine, Italy

Coordinator, European Reference Network For Hereditary Metabolic Diseases (MetabERN)

Professor of Pediatrics University of Padova Italy



Hiroyuki Sonoda, PhD

Senior Vice President, Head of Research JCR Pharmaceuticals Co., Ltd.

Co-Sponsored by: ICIEM2025 and JCR Pharmaceuticals Co., Ltd.

